SS
Sam Slutsky
Compare →Managing Director, Sr. Research Analyst at LifeSci Capital
Sam Slutsky is a Senior Research Analyst at LifeSci Capital, specializing in smid-cap biotech investments. With over 13 years of experience, he has been recognized for his stock ratings and analysis in the healthcare sector, contributing significantly to the firm's research output.
No chart yet. A chart needs 8 resolved predictions, and Sam has 7. The predictions themselves are below.
SORT
STILL OPEN
?
Sign in to read this call.
Due Dec 31, 2026August 14, 2026PharmaceuticalsClinical TrialsPending
—
SCORE
?
Sign in to read this call.
Due Dec 31, 2026August 12, 2024biotechfinancial healthPending
—
SCORE
?
Sign in to read this call.
Due Jan 27, 2027 (12 months assumed)January 27, 2026BiotechInvestmentPending
—
SCORE
?
Sign in to read this call.
Due Apr 21, 2027 (12 months assumed)April 21, 2026BiotechInvestmentPending
—
SCORE
?
Sign in to read this call.
Due May 9, 2027 (12 months assumed)May 9, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
Due May 16, 2027 (12 months assumed)May 16, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
Due May 17, 2027 (12 months assumed)May 17, 2026HealthcarePharmaceuticalsPending
—
SCORE
?
Sign in to read this call.
Due May 23, 2027 (12 months assumed)May 23, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
Due May 23, 2027 (12 months assumed)May 23, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
Due Jul 31, 2027 (12 months assumed)July 31, 2026HealthcarePharmaceuticalsPending
—
SCORE
?
Sign in to read this call.
Due Aug 4, 2027 (12 months assumed)August 4, 2026HealthcarePharmaceuticalsPending
—
SCORE
?
Sign in to read this call.
Due Aug 14, 2027 (12 months assumed)August 14, 2026PharmaceuticalsInvestmentPending
—
SCORE
?
Damora Therapeutics will reach a price of $45 within 12 months of Sep 18, 2026.
Due Sep 18, 2027September 18, 2026Price targetEquitiesPending
—
SCORE
?
Olema Pharmaceuticals will reach a price of $16 within 12 months of Sep 19, 2026.
Due Sep 19, 2027September 19, 2026Price targetEquitiesPending
—
SCORE
?
Celldex Therapeutics will reach a price of $56 within 12 months of Sep 20, 2026.
Due Sep 20, 2027September 20, 2026Price targetEquitiesPending
—
SCORE
?
ABIVAX Société Anonyme will reach a price of $168 within 12 months of Sep 22, 2026.
Due Sep 22, 2027September 22, 2026Price targetEquitiesPending
—
SCORE
?
Oruka Therapeutics will reach a price of $175 within 12 months of Sep 23, 2026.
Due Sep 23, 2027September 23, 2026Price targetEquitiesPending
—
SCORE
?
Immunovant will reach a price of $53 within 12 months of Sep 26, 2026.
Due Sep 26, 2027September 26, 2026Price targetEquitiesPending
—
SCORE
?
Pyxis Oncology will reach a price of $8 within 12 months of Sep 26, 2026.
Due Sep 26, 2027September 26, 2026Price targetEquitiesPending
—
SCORE
?
Abivax could see a multi-fold increase in value if its Phase 3 data are positive.
October 2026BiotechPharmaceuticalsPending
—
SCORE
?
Sam Slutsky set a price target of $103.00 for Spyre Therapeutics.
October 2026HealthcarePending
—
SCORE
?
Sign in to read this call.
September 14, 2026Price targetEquitiesPending
—
SCORE
?
Sign in to read this call.
July 29, 2026FinanceBiotechPending
—
SCORE
?
Sign in to read this call.
June 29, 2026HealthcareBiotechPending
—
SCORE
?
Sign in to read this call.
June 29, 2026FinanceInvestmentPending
—
SCORE
?
Sign in to read this call.
May 16, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
May 16, 2026StockInvestmentPending
—
SCORE
?
Sign in to read this call.
April 9, 2026HealthcareBiotechPending
—
SCORE
?
Sign in to read this call.
January 27, 2026stocksinvestmentPending
—
SCORE
?
Sign in to read this call.
January 8, 2026Stock RatingPending
—
SCORE
?
Sign in to read this call.
August 14, 2025HealthcareFDA ApprovalPending
—
SCORE
RESOLVED · NEWEST FIRST
◇
Sign in to read this call.
August 14, 2026PharmaceuticalsClinical TrialsToo vague to check
—
SCORE
✓
Sign in to read this call.
June 11, 2026call #7StockInvestmentCorrect
82
SCORE
✓
Sign in to read this call.
March 3, 2026call #6PharmaceuticalsDrug DevelopmentCorrect
52
SCORE
◇
Palvella Therapeutics will reach a price target of $90.00 within 12 months.
August 4, 2025HealthcareBiotechnologyNot settleable
—
SCORE
◑
Sign in to read this call.
August 4, 2025call #5Stock RatingPartial
23
SCORE
✗
Sign in to read this call.
July 23, 2025call #4HealthcareBiotechnologyWrong
0
SCORE
◑
Sign in to read this call.
August 12, 2024call #2biotechclinical trialsPartial
75
SCORE
✗
Sign in to read this call.
August 12, 2024call #3biotechclinical trialsWrong
0
SCORE
◇
Sign in to read this call.
July 16, 2024clinical trialsmarket penetrationNo verdict
—
SCORE
◇
Sign in to read this call.
own side · their own organization · resolved, earns no score
May 7, 2024clinical trialsbiopharmaceuticalsNo verdict
—
SCORE
◇
Sign in to read this call.
March 26, 2024HealthcarePharmaceuticalsNot settleable
—
SCORE
✓
Sign in to read this call.
March 15, 2024call #1clinical trialsCMLCorrect
85
SCORE
◇
Sign in to read this call.
April 12, 2023Stock RatingNot settleable
—
SCORE
◇
Sign in to read this call.
April 5, 2023Stock RatingNot settleable
—
SCORE
◇
Sign in to read this call.
January 14, 2019clinical trialscancerNo verdict
—
SCORE
◇
Sign in to read this call.
October 30, 2018oncologygene therapyNo verdict
—
SCORE
✓
Sign in to read this call.
own side · their own organization · resolved, earns no score
October 30, 2018clinical trialsoncologyCorrect
—
SCORE
◇
Sign in to read this call.
own side · their own organization · resolved, earns no score
October 30, 2018clinical trialsoncologyNo verdict
—
SCORE
Still open · 31
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2026Said August 14, 2026PharmaceuticalsClinical Trials
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2026Said August 12, 2024biotechfinancial health
?No market prices this claim
Sign in to read this call.
Due Jan 27, 2027 (12 months assumed)Said January 27, 2026BiotechInvestment
?No market prices this claim
Sign in to read this call.
Due Apr 21, 2027 (12 months assumed)Said April 21, 2026BiotechInvestment
?No market prices this claim
Sign in to read this call.
Due May 9, 2027 (12 months assumed)Said May 9, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Due May 16, 2027 (12 months assumed)Said May 16, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Due May 17, 2027 (12 months assumed)Said May 17, 2026HealthcarePharmaceuticals
?No market prices this claim
Sign in to read this call.
Due May 23, 2027 (12 months assumed)Said May 23, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Due May 23, 2027 (12 months assumed)Said May 23, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Due Jul 31, 2027 (12 months assumed)Said July 31, 2026HealthcarePharmaceuticals
?No market prices this claim
Sign in to read this call.
Due Aug 4, 2027 (12 months assumed)Said August 4, 2026HealthcarePharmaceuticals
?No market prices this claim
Sign in to read this call.
Due Aug 14, 2027 (12 months assumed)Said August 14, 2026PharmaceuticalsInvestment
?No market prices this claim
Damora Therapeutics will reach a price of $45 within 12 months of Sep 18, 2026.
Due Sep 18, 2027Said September 18, 2026Price targetEquities
?No market prices this claim
Olema Pharmaceuticals will reach a price of $16 within 12 months of Sep 19, 2026.
Due Sep 19, 2027Said September 19, 2026Price targetEquities
?No market prices this claim
Celldex Therapeutics will reach a price of $56 within 12 months of Sep 20, 2026.
Due Sep 20, 2027Said September 20, 2026Price targetEquities
?No market prices this claim
ABIVAX Société Anonyme will reach a price of $168 within 12 months of Sep 22, 2026.
Due Sep 22, 2027Said September 22, 2026Price targetEquities
?No market prices this claim
Oruka Therapeutics will reach a price of $175 within 12 months of Sep 23, 2026.
Due Sep 23, 2027Said September 23, 2026Price targetEquities
?No market prices this claim
Immunovant will reach a price of $53 within 12 months of Sep 26, 2026.
Due Sep 26, 2027Said September 26, 2026Price targetEquities
?No market prices this claim
Pyxis Oncology will reach a price of $8 within 12 months of Sep 26, 2026.
Due Sep 26, 2027Said September 26, 2026Price targetEquities
?No market prices this claim
Abivax could see a multi-fold increase in value if its Phase 3 data are positive.
Said October 2026BiotechPharmaceuticals
?No market prices this claim
Sam Slutsky set a price target of $103.00 for Spyre Therapeutics.
Said October 2026Healthcare
?No market prices this claim
Sign in to read this call.
Said September 14, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Said July 29, 2026FinanceBiotech
?No market prices this claim
Sign in to read this call.
Said June 29, 2026HealthcareBiotech
?No market prices this claim
Sign in to read this call.
Said June 29, 2026FinanceInvestment
?No market prices this claim
Sign in to read this call.
Said May 16, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Said May 16, 2026StockInvestment
?No market prices this claim
Sign in to read this call.
Said April 9, 2026HealthcareBiotech
?No market prices this claim
Sign in to read this call.
Said January 27, 2026stocksinvestment
?No market prices this claim
Sign in to read this call.
Said January 8, 2026Stock Rating
?No market prices this claim
Sign in to read this call.
Said August 14, 2025HealthcareFDA Approval